Entropy Neurodynamics Limited has released a press release.
TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- $847,186 R&D Tax Incentive received
- First BED patient completes second TRP-8803 infusion
- First patient successfully dosed in TRP 8803 BED trial
- BED trial accelerates - enrolment grows, dosing in two weeks
- $6.1m in new funding to accelerate clinical development
Later from Entropy Neurodynamics
- First TRP-8803 BED patient shows broad clinical improvement
- Quarterly Activities Report and Appendix 4C
- Australian Patent Secures TRP 8803 Platform to 2042
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics